Barbara Uherek received her training as a licensed medical technical assistant in Würzburg. She initially joined the group as a technician in 1999, but left in 2002 to start a family and take care of her children. After this parental leave, Barbara returned to the group in 2010.
Anne Scherer received her Master's degree in Biomedicine from the University of Mainz. In her Master’s thesis she established a qRT-PCR-based assay for the detection of oncogenic driver mutations in tumor-derived exosomes to select non-small cell lung cancer patients for targeted therapy. Anne joined the group as a Ph.D. student in 2019. In her thesis project she is developing novel bispecific antibodies for tumor targeting.
Jasmin Röder received her Master’s degree in Biology from the University of Mainz. In her Master’s thesis she contributed to the development of an autochthonous mouse model of non-small cell lung cancer (NSCLC) for the evaluation of CAR-engineered T cells. Jasmin joined the group as a Ph.D. student in 2017. In her thesis project she is establishing innovative mouse breast cancer models to investigate the antitumor activity of NK cells.
Dr. Pranav Oberoi
Pranav Oberoi obtained his master’s degree in neuroscience from the National Brain Research Centre (India), focusing on the role of protein kinases in photoreceptor development. He initially joined the research group for his doctoral studies with emphasis on granzyme B fusion proteins as tools for targeted tumor therapy. Since receiving his PhD degree in pharmaceutical sciences from the University of Frankfurt am Main in 2013, Pranav is a postdoctoral fellow in the group investigating novel approaches to generate genetically modified primary NK cells and enhance their antitumoral activity.
Thorsten Geyer obtained his Diploma in Biology from the University of Mainz. He joined the group as a technician in 1998. Thorsten also serves as the Safety Officer of the Georg-Speyer-Haus.
Malena Bodden received her Master’s degree in Biomedical Science from the University of Marburg. In her Master’s thesis she investigated the mRNA and miRNA profile of macrophages upon stimulation with pro- and anti-inflammatory cytokines in the context of eosinophilic airway inflammation. Malena joined the group as a Ph.D. student in 2017. In her thesis project she is developing genetically engineered NK cells for cancer immunotherapy.
Anita Bhatti received her Master's degree in Biomedicine from the University of Mainz. In her doctoral studies, also at the University of Mainz, she evaluated CAR-engineered T cells as a tool for adoptive cellular therapy of non-small cell lung cancer. Anita joined the group as a postdoctoral fellow in 2019, investigating strategies to modulate the tumor microenvironment and endogenous antitumor immune responses with genetically modifed lymphocytes.
Idan Ben Horin
Idan Ben Horin received his MD degree from the Hebrew University of Jeruslaem in Israel. In his thesis he investigated the role of NFκB in the development of meningiomas. He completed his residency in Medical Oncology at the Tel-Aviv Sourasky Medical Center, where his research focused on the characterization of T cells in primary brain tumors. Idan joined the group as a PhD candidate in 2018. In his thesis project he is studying the effects of CAR-engineered immune cells in humanized mouse models.
Jordi Pfeifer Serrahima
Jordi Pfeifer Serrahima joined the group in 2019 to work on his Master’s thesis focusing on the generation and functional characterization of bispecific antibodies that redirect cytotoxic lymphocytes to tumor cells. Since receiving his Master's degree in Molecular Biotechnology from the Technical University of Darmstadt, Jordi is continuing this work as a Ph.D. student.
Aline Häcker received her Master's degree in Technical Biology from the University of Stuttgart. In her Master's thesis she investigated the cell cycle-dependency of death receptor-mediated apoptosis. Aline joined the group as a Ph.D. student in 2016. In her thesis project she is developing immunocytokines to improve the antitumor activity of CAR-modified lymphocytes.